Payers Want Deep Discounts To Make Biosimilars Worth Their While
Executive Summary
Interviews with US payers suggest that some expect discounts of 40%-50% off prices of branded drugs and that many insurers are more focused on promoting use of biosimilars in new starts, rather than switching stable patients.
You may also be interested in...
2017 – Scrip Readers’ Pharma Year In Review
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
2017 – Scrip Readers’ Pharma Year In Review
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018
Sandoz needs to do another study to satisfy FDA, while Amgen says it faces a slow pace of patent litigation with AbbVie.